Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 775.00 GBp
Change Today -20.00 / -2.52%
Volume 3.3K
DDDD On Other Exchanges
As of 11:35 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

4d pharma plc (DDDD) Snapshot

795.00 GBp
Previous Close
795.00 GBp
Day High
795.00 GBp
Day Low
775.00 GBp
52 Week High
05/22/15 - 1,045 GBp
52 Week Low
12/11/14 - 320.00 GBp
Market Cap
Average Volume 10 Days
-0.05 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for 4D PHARMA PLC (DDDD)

Related News

No related news articles were found.

4d pharma plc (DDDD) Related Businessweek News

No Related Businessweek News Found

4d pharma plc (DDDD) Details

4D pharma plc researches and develops pharmaceutical products in new live biotherapeutic areas in the United Kingdom. Its first generation programs include Blautix, a treatment for irritable bowel syndrome; Thetanix, a treatment for paediatric Crohn’s; and Rosburix, a treatment for paediatric ulcerative colitis. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is based in Manchester, the United Kingdom.

13 Employees
Last Reported Date: 06/4/15
Founded in 2014

4d pharma plc (DDDD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 97.0K GBP
Chief Scientific Officer and Director
Total Annual Compensation: 97.0K GBP
Compensation as of Fiscal Year 2014.

4d pharma plc (DDDD) Key Developments

4D pharma plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015

4D pharma plc announced unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported operating loss of £4.47 million against £0.567 million a year ago. Loss before tax was £4.27 million against profit of £0.462 million a year ago. Loss for the period and total comprehensive income from the period was £4.27 million against profit of £0.462 million a year ago. Basic and diluted loss per share was 6.93 pence against profit of 1.54 pence a year ago. Cash outflow from operating activities was £4.180 million against £0.690 million a year ago. Purchases of property, plant and equipment was £0.226 million against £0.024 million a year ago.

4D Pharma plc Provides Clinical Trial Update

4D pharma plc announced that it has commenced dosing in a phase 1 clinical trial for the treatment of Irritable bowel syndrome (IBS). IBS is a functional bowel disorder characterized by discomfort, pain and changes in bowel habits. Symptoms can be mild, moderate or severe. Mild symptoms, which occur infrequently, can sometimes interfere with normal daily functioning. Moderate symptoms are more intense, occur more frequently, and often interfere with daily functioning. Severe symptoms chronically interfere with daily functioning. It is estimated that 10-15% of the population have IBS, with only 30-35% of patients seeking medical attention, the majority of which have persistent symptoms. There are currently few approved treatment options, all of which focus on the modulation of symptoms. The clinical trial will assess the safety and tolerability of Blautix in a number of healthy volunteers and individuals with IBS. In addition, clinical symptoms and biomarkers relevant to the mechanism of action of Blautix will be assessed. The trial is expected to be completed in late 2015.

4D Pharma plc Provides Research Update on MicroRx, its Proprietary Platform for the Discovery of Novel Live Biotherapeutics

4D pharma plc provides the research update on MicroRx, its proprietary platform for the discovery of novel live biotherapeutics. Using its MicroRx platform, the company has already identified candidates for severe asthma, allergic asthma and rheumatoid arthritis. The company continues to expand its drug development pipeline and reported that the company has identified bacteria that have therapeutically relevant effects in an industry standard model of multiple sclerosis. The preliminary pre-clinical work, conducted externally, showed the prevention of the development of the disease with demonstrably clear efficacy.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DDDD:LN 775.00 GBp -20.00

DDDD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DDDD.
View Industry Companies

Industry Analysis


Industry Average

Valuation DDDD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales NM Not Meaningful
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 4D PHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at